AAV-TNNI3 rescues an experimental murine Tnni3 mutation resulting in thin filament mediated DCM.
Publication Year:
2026
PubMed ID:
41494578
Funding Grants:
Public Summary:
Dilated cardiomyopathy (DCM) is a heart condition in which the heart muscle becomes enlarged and weakened, making it harder for the heart to pump blood effectively. Some cases are caused by mutations in the TNNI3 gene, which provides instructions for making a protein called cardiac troponin I. This protein plays an important role in controlling heart muscle contraction. Currently, treatment options for people with TNNI3-related cardiomyopathy remain limited.
This study investigated whether gene therapy could prevent heart damage caused by a mutation in the Tnni3 gene. The researchers used a mouse model carrying an experimental Tnni3 mutation that leads to the gradual development of dilated cardiomyopathy and eventually heart failure.
To investigate a potential treatment, the researchers used an adeno-associated virus (AAV), a modified virus commonly used to deliver genetic material into cells. The virus carried a healthy human version of the TNNI3 gene, with the aim of replacing the function of the mutated gene.
The results showed that mice receiving the AAV-TNNI3 treatment were protected against the development of dilated cardiomyopathy at the four-month evaluation point. The treatment prevented the heart-related abnormalities associated with the genetic mutation, suggesting that providing a healthy version of the gene can help preserve heart function even when a functional but abnormal protein is already present.
Overall, this study provides promising evidence that gene replacement therapy may offer a new approach to treating inherited heart diseases caused by TNNI3 mutations. These findings could help expand the potential applications of gene therapy beyond conditions involving missing or insufficient proteins. However, further research is needed to evaluate the long-term safety and effectiveness of this approach before it can be considered for human treatment.
Scientific Abstract:
Cardiac thin filament mutations in TNNI3 are associated with up to 3 % of hypertrophic (HCM) cardiomyopathy cases and contribute to severe restrictive (RCM) and dilated (DCM) cardiomyopathy caseloads. As such, thin filament cardiomyopathy mediated by TNNI3 mutations is an orphan disease with unmet therapeutic need. Gene therapy is one approach to addressing orphan disease but has been restricted to the repletion of protein deficiency. Based on the best available knowledge, TNNI3 gene therapy has never been applied in the context of a functional mutant protein. Described here is the viral gene therapy rescue at a 4-month endpoint of an experimental murine Tnni3 mutation resulting in slow-onset dilated cardiomyopathy (DCM) with cardiac failure at 12-18 months. Mutant mice treated with AAV encoding wild-type (WT) human TNNI3 at 1.0E+14 vg/kG prevented the onset of DCM pathology. This work describes the first adeno-associated virus (AAV) gene therapy replacement of functional mutated Tnni3 protein. The results suggest a broader application of gene therapy for gene replacement.